There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oncternal Therapeutics (ONCT – Research Report), Allena Pharmaceuticals (ALNA – Research Report) and Gritstone Oncology (GRTS – Research Report) with bullish sentiments.
Oncternal Therapeutics (ONCT)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oncternal Therapeutics today and set a price target of $9.00. The company’s shares closed last Tuesday at $2.34.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Oncternal Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.
See the top stocks recommended by analysts >>
Allena Pharmaceuticals (ALNA)
H.C. Wainwright analyst Edward White maintained a Buy rating on Allena Pharmaceuticals today and set a price target of $11.00. The company’s shares closed last Tuesday at $0.58.
According to TipRanks.com, White is a 4-star analyst with an average return of
Allena Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.
Gritstone Oncology (GRTS)
H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Gritstone Oncology today and set a price target of $24.00. The company’s shares closed last Tuesday at $7.02, close to its 52-week low of $3.00.
According to TipRanks.com, CFA is a 2-star analyst with an average return of
Currently, the analyst consensus on Gritstone Oncology is a Moderate Buy with an average price target of $17.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ONCT:
